A U.S. judge on Friday said two patents relating to Amgen Inc's blockbuster...
- A U.S. judge on Friday said two patents relating to Amgen Inc’s blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.
U.S. District Judge Claire Cecchi in Newark, New Jersey rejected arguments by Novartis’ Sandoz unit that the patents covering Enbrel’s active ingredient until 2029 should not have been granted because their concepts were already contained in previous patents.
Enbrel generated $5.01 billion in sales for Amgen in 2018 and belongs to a class of medicine known as biologics, made from living cells and are therefore difficult to copy with precision. Amgen has the exclusive rights to patents originally granted to F. Hoffmann-La Roche AG on etanercept, the protein in Enbrel.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Bayer, Elanco aiming to reach animal-health deal next week - BloombergGermany's Bayer AG and U.S. drug firm Elanco Animal Health Inc aim to reach...
Baca lebih lajut »
FDA tells four firms to stop selling flavored e-cigarette, hookah productsThe U.S. Food and Drug Administration has told four companies to remove 44 of th...
Baca lebih lajut »
Canada enacts drug price crackdown, in blow to pharmaceutical industryThe Canadian government on Friday announced final regulations to reduce patented...
Baca lebih lajut »
Can Canadian imports lower U.S. drug prices?A new proposal from the Trump administration could allow Americans to import cheaper prescription drugs from Canada. Is this a solution to steep drug costs in the U.S.?
Baca lebih lajut »
U.S.-China Trade Battle Is Crimping Global Oil DemandWorries about the health of the world’s economy and increasingly uncertain trade relations between the U.S. and China will put further pressure on global oil demand in 2019, the International Energy Agency said.
Baca lebih lajut »